Tirzepatide 5mg
Size: 5mg | 99% Purity
M.Wt: 4813.48
Formula: C225H348N48O68
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: Not established
CAS No.: 2023788-19-2
| Available sizes | 0.05kg |
|---|---|
| Purity (HPLC) | >99% |
| Molecular weight | 4813.48 g/mol |
| Molecular formula | C225H348N48O68 |
| CAS number | 2023788-19-2 |
| Synonyms | LY3298176, GIP/GLP-1 Dual Agonist, Mounjaro Active Compound |
| Solubility | H2O |
| Storage | -20°C / 3 years |
| Half-life | Not established |
Peptide sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2Only 6 left in stock
Research reference: View mechanism, literature and identifier graph →
Reconstitution calculator (pre-filled for 5 mg)
HPLC and MS verified by UKAS-accredited laboratories.
Free on orders over £50. Next-day upgrade available.
COA and batch number on every vial.
Tirzepatide 5mg — research reference material
Tirzepatide 5mg is supplied by NMChem as a research reference material in a 5mg presentation. Compound class: GIP/GLP-1 dual receptor agonist · 39-residue peptide, characterised in the literature as a incretin receptor agonist. It is supplied strictly for in-vitro laboratory research and is not for human or veterinary use.
Research context
GLP-1/GIP agonist; studied in glucose, metabolic-weight research. Full mechanism detail, the identifier graph and selected peer-reviewed literature are set out on our Tirzepatide research reference. Related compounds in the same research area: Semaglutide, Retatrutide, Cagrilintide. You can also compare it side by side on our comparison tool.
Presentation
This listing is the 5mg presentation at >99% stated purity, catalogue reference TIR5.
Identifiers
- CAS number: 2023788-19-2
- Molecular formula: C225H348N48O68
- Molecular weight: 4813.48 g/mol
- Synonyms: LY3298176, GIP/GLP-1 Dual Agonist, Mounjaro Active Compound
- Class: GIP/GLP-1 dual receptor agonist · 39-residue peptide
Format & quality
Supplied as 5mg at >99% purity. Identity and purity are characterised by reversed-phase HPLC and mass spectrometry, with a per-batch Certificate of Analysis available on request. This item is a lyophilised powder and requires reconstitution before use; bacteriostatic water is supplied separately, and our reconstitution guide covers volumes and concentrations. Solubility: H2O.
Storage
Store at -20°C, protected from light. Stated shelf life 3 years from date of manufacture. Always confirm against the Certificate of Analysis supplied with your batch.
Research use only — not for human or veterinary use, food, cosmetic or therapeutic application. NMChem supplies this item as a laboratory reference material; no dosing or administration guidance is provided.
Frequently asked questions
What is Tirzepatide 5mg?
GIP/GLP-1 dual receptor agonist · 39-residue peptide. GLP-1/GIP agonist; studied in glucose, metabolic-weight research. NMChem supplies it as a research reference material only.
What is the CAS number for Tirzepatide 5mg?
2023788-19-2. Molecular formula C225H348N48O68. Molecular weight 4813.48 g/mol.
How should Tirzepatide 5mg be stored?
At -20°C, protected from light, with a stated shelf life of 3 years. The batch Certificate of Analysis is the controlling document.
Certificate of Analysis
Reconstitution
For peptides supplied as lyophilised powder, reconstitute in bacteriostatic water or sterile saline at the concentration appropriate to your protocol. Allow the vial to come to room temperature before opening, add solvent slowly down the inside wall (do not directly onto the powder), and gently invert until clear. Do not vortex.
Reconstituted solutions are typically stable at 2–8°C for the durations published in the corresponding peer-reviewed reference. For long-term storage, aliquot and freeze at −20°C; avoid repeated freeze–thaw cycles.
Research literature
Selected peer-reviewed publications from PubMed referencing this compound. Provided for research orientation — not an endorsement of any clinical application. Each citation links to the canonical PubMed record.
-
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T et al. · Molecular metabolism · 2018
PubMed PMID 30473097 -
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ et al. · JAMA · 2024
PubMed PMID 38078870 -
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP et al. · Lancet (London, England) · 2018
PubMed PMID 30293770
You may also need
Related compounds
